Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug

L. Brusa, A. Bassi, G. Lunardi, E. Fedele, A. Peppe, A. Stefani, P. Pasqualetti, P. Stanzione, M. Pierantozzi

Research output: Contribution to journalArticlepeer-review


Background: Entacapone is a COMT inhibitor used in Parkinson's disease (PD) patients, as an adjunctive therapy to L-dopa in order to prolong its bioavailability and thus its clinical effect. However, previous studies reported entacapone-induced L-dopa to have lower Cmax and delayed t max values, coupled with a delayed onset of the clinical effect, possibly suggesting an interference between the two drugs. The aim of our study was to evaluate whether a delayed entacapone administration in association with standard L-dopa/carbidopa, may in some subjects improve the entacapone effects on L-dopa AUC and thus on the clinical 'on time' duration. Methods: Twenty-eight idiopathic advanced PD patients were blindly evaluated in three different test days, following administration of carbidopa/L-dopa or carbidopa/ L-dopa plus co-administered entacapone or plus entacapone administered with 30 min of delay. Results: The AUC, the 'on time' and UPDRS score of the whole group were improved by both modalities of entacapone administration. An ex post analysis showed that the delayed entacapone administration produced a significant improvement in a subgroup of 10 non-responding patients to the co-administration. Conclusion: We suggest that the delayed administration should be attempted in the subjects not improved by entacapone co-administration.

Original languageEnglish
Pages (from-to)593-606
Number of pages14
JournalEuropean Journal of Neurology
Issue number9
Publication statusPublished - Sep 2004


  • Delayed administration
  • Entacapone
  • L-dopa pharmacokinetic
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)


Dive into the research topics of 'Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug'. Together they form a unique fingerprint.

Cite this